The Life Sciences team advised Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) on its initial public offering of 11,700,000 shares of common stock at a public offering price of $19 per share. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Monte Rosa, were approximately $222.3 million. In addition, Monte Rosa has granted the underwriters a 30-day option to purchase up to an additional 1,755,000 shares of common stock at the initial public offering price.

Monte Rosa is a biotechnology company developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins.

The Goodwin team was led by Robert Puopolo, Marishka DeToy, Dan Hughes and included Cathy McCarty (IP); Sarah BockJennifer Fay and Caroline Galiatsos (Employment); Alexander Varond, Seth Gitner, and Simone Otenaike (Regulatory); Noelle Dubiansky (Licensing); and Dan Karelitz (Tax).

For more details, read the press release and articles in Endpoints, Fierce Biotech, and MarketWatch.